tetano
Editor, Senior Moderator
Reumatol Clin (Engl Ed)
. 2021 Dec;17(10):559-561.
doi: 10.1016/j.reumae.2020.06.008. Epub 2020 Oct 15.
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab
Luis Figuero-Pérez[SUP] 1 [/SUP], Alejandro Olivares-Hernández[SUP] 2 [/SUP], Roberto A Escala-Cornejo[SUP] 3 [/SUP], Eduardo Terán-Brage[SUP] 2 [/SUP], Álvaro López-Gutiérrez[SUP] 2 [/SUP], Juan J Cruz-Hernández[SUP] 2 [/SUP]
Affiliations
Abstract
SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory response, and simulate haemophagocytic lymphohistiocytosis. Several studies have proposed that anti-IL-6 receptor antibodies, such as tocilizumab, play an important role in the treatment of severe acute respiratory infection associated with SARS-CoV-2. However, the role of anti-IL-1 receptor antibodies, such as anakinra, in the treatment of COVID-19 has not been established. We present a case report of a 51-year-old man diagnosed with severe respiratory infection associated with SARS-CoV-2 that was refractory to antiviral and anti-IL-6 treatment, with a favourable clinical outcome and analytical improvement after treatment with anti-IL-1 (anakinra).
Keywords: Anakinra; Cytokine storm; SARS-CoV-2; Tocilizumab; Tormenta de citoquinas.
. 2021 Dec;17(10):559-561.
doi: 10.1016/j.reumae.2020.06.008. Epub 2020 Oct 15.
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab
Luis Figuero-Pérez[SUP] 1 [/SUP], Alejandro Olivares-Hernández[SUP] 2 [/SUP], Roberto A Escala-Cornejo[SUP] 3 [/SUP], Eduardo Terán-Brage[SUP] 2 [/SUP], Álvaro López-Gutiérrez[SUP] 2 [/SUP], Juan J Cruz-Hernández[SUP] 2 [/SUP]
Affiliations
- PMID: 34823820
- DOI: 10.1016/j.reumae.2020.06.008
Abstract
SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory response, and simulate haemophagocytic lymphohistiocytosis. Several studies have proposed that anti-IL-6 receptor antibodies, such as tocilizumab, play an important role in the treatment of severe acute respiratory infection associated with SARS-CoV-2. However, the role of anti-IL-1 receptor antibodies, such as anakinra, in the treatment of COVID-19 has not been established. We present a case report of a 51-year-old man diagnosed with severe respiratory infection associated with SARS-CoV-2 that was refractory to antiviral and anti-IL-6 treatment, with a favourable clinical outcome and analytical improvement after treatment with anti-IL-1 (anakinra).
Keywords: Anakinra; Cytokine storm; SARS-CoV-2; Tocilizumab; Tormenta de citoquinas.